Cefuroxime Sodium
The sodium salt form of cefuroxime is used parenterally for moderate to severe bacterial infections and for surgical prophylaxis. It provides the second-generation cephalosporin spectrum of activity of the parent compound against gram-positive and gram-negative pathogens. Dose adjustment is required in patients with significant renal impairment.
الوزن الجزيئي
446,4000 g/mol
TPSA
202,00 Ų
المجالات العلاجية
آلية العمل
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(N)=O)CS[C@H]12)c1ccco1.[Na+]
InChI
InChI=1S/C16H16N4O8S.Na/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20;/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24);/q;+1/p-1/b19-9-;/t10-,14-;/m1./s1
Molecular Formula
C16H15N4NaO8S
HBD / HBA
2 / 10
الروابط القابلة للدوران
8
الذرات الثقيلة
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
The sodium salt form of cefuroxime is used parenterally for moderate to severe bacterial infections and for surgical prophylaxis. It provides the second-generation cephalosporin spectrum of activity of the parent compound against gram-positive and gram-negative pathogens. Dose adjustment is required in patients with significant renal impairment.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefuroxime Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2146124. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 23670318. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefuroxime-sodium"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefuroxime-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefuroxime-sodium/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefuroxime-sodium/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefuroxime-sodium"></drugfyi-drug>